Bio-Path Holdings Advances in RNAi Therapeutics with Promising Clinical Trials
TL;DR
Bio-Path Holdings' innovative DNAbilize® technology and diverse pipeline, including prexigebersen for AML, positions it as a potential leader in RNAi therapeutics, offering a competitive edge in biotech investments.
Bio-Path Holdings utilizes its DNAbilize® platform to deliver antisense oligonucleotides with enhanced stability and uptake, currently testing prexigebersen in Phase 2 trials for AML and exploring treatments for solid tumors and metabolic diseases.
Bio-Path Holdings' research into RNAi therapeutics like prexigebersen could revolutionize treatment for AML, solid tumors, and metabolic diseases, significantly improving patient outcomes and quality of life.
Discover how Bio-Path Holdings' DNAbilize® technology is breaking barriers in drug delivery, with promising candidates for leukemia, solid tumors, and even obesity and diabetes treatments.
Found this article helpful?
Share it with your network and spread the knowledge!
Bio-Path Holdings, Inc. (OTCQB: BPTH), a clinical-stage biotechnology company, is making notable progress with its RNA interference (RNAi) therapeutics, leveraging its proprietary DNAbilize® platform. This technology enhances the delivery of antisense oligonucleotides, improving drug stability and cellular uptake while reducing toxicity. The company's lead candidate, prexigebersen (BP1001), is currently in Phase 2 trials for acute myeloid leukemia (AML), with a modified version, BP1001-A, showing promise in Phase 1/1b trials for solid tumors and preclinical studies for obesity and type 2 diabetes.
Another candidate, BP1002, targeting the Bcl-2 protein, is under evaluation for blood cancers and solid tumors, with a Phase 1 trial for refractory/relapsed AML progressing to its fourth dose cohort. Additionally, BP1003, a STAT3 inhibitor aimed at pancreatic cancer, is in pre-clinical development, demonstrating success in penetrating pancreatic tumors in previous studies.
Bio-Path's DNAbilize® technology represents a breakthrough in antisense and liposome delivery, offering a novel approach to treating a wide range of indications, including cancer. The company's strong intellectual property position and strategic relationships with leading cancer centers underscore its potential to revolutionize RNAi therapeutics. Despite a reported cash on hand of $122,000 as of March 31, 2025, and the need for additional funding, Bio-Path's pipeline of drug candidates and nearing Phase 2 milestones suggest significant undervaluation compared to peers.
The advancements in Bio-Path's clinical trials and technology platform highlight the importance of RNAi therapeutics in addressing unmet medical needs in oncology and metabolic diseases. The potential approval of its lead drug candidates could have a profound impact on patients worldwide, offering new hope for those with limited treatment options.
Curated from Reportable
